

Experiment Number: 91014-06
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/TG.AC HEMI

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)

CAS Number: 93-83-4

Date Report Requested: 10/23/2014

Time Report Requested: 09:28:42

First Dose M/F: NA / NA

Lab: ILS

| | |
|-----------------------------|------------|
| C Number: | C91014C |
| Lock Date: | 08/21/1997 |
| Cage Range: | All |
| Date Range: | All |
| Reasons For Removal: | All |
| Removal Date Range: | All |
| Treatment Groups: | All |
| Study Gender: | Female |
| PWG Approval Date | NONE |

Experiment Number: 91014-06

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/TG.AC HEMI

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)

CAS Number: 93-83-4

Date Report Requested: 10/23/2014

Time Report Requested: 09:28:42

First Dose M/F: NA / NA

Lab: ILS

| TG.AC HEMI Mouse FEMALE | 0 MG | 1.50 UG TPA | 0.4 MG | 0.8 MG | 1.2 MG |
|-----------------------------------|----------|-------------|--------|--------|----------|
| Disposition Summary | | | | | |
| Animals Initially In Study | 20 | 10 | 15 | 15 | 19 |
| Early Deaths | | | | | |
| Moribund Sacrifice | 2 | 1 | | | 1 |
| Natural Death | 1 | | 1 | 1 | 2 |
| Survivors | | | | | |
| Terminal Sacrifice | 15 | 7 | 14 | 13 | 13 |
| Other | 2 | 2 | | 1 | 3 |
| Animals Examined Microscopically | 15 | | | | 13 |
| ALIMENTARY SYSTEM | | | | | |
| Esophagus | (0) | (0) | (0) | (0) | (1) |
| Squamous Cell Papilloma, Multiple | | | | | 1 (100%) |
| Liver | (15) | (0) | (0) | (0) | (13) |
| Salivary Glands | (15) | (0) | (0) | (0) | (13) |
| Duct, Sublingual Gl, Adenoma | | | | | 1 (8%) |
| Stomach, Forestomach | (15) | (0) | (0) | (0) | (13) |
| Squamous Cell Papilloma | 3 (20%) | | | | 1 (8%) |
| Squamous Cell Papilloma, Multiple | | | | | 1 (8%) |
| Stomach, Glandular | (15) | (0) | (0) | (0) | (13) |
| Tongue | (2) | (0) | (0) | (0) | (3) |
| Squamous Cell Carcinoma | 2 (100%) | | | | |
| Squamous Cell Papilloma | 1 (50%) | | | | 1 (33%) |
| Tooth | (0) | (0) | (0) | (0) | (1) |
| Odontoma | | | | | 1 (100%) |
| CARDIOVASCULAR SYSTEM | | | | | |
| None | | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 91014-06

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/TG.AC HEMI

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)

CAS Number: 93-83-4

Date Report Requested: 10/23/2014

Time Report Requested: 09:28:42

First Dose M/F: NA / NA

Lab: ILS

| TG.AC HEMI Mouse FEMALE | 0 MG | 1.50 UG TPA | 0.4 MG | 0.8 MG | 1.2 MG |
|-------------------------------|--------|-------------|--------|--------|---------|
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (15) | (0) | (0) | (0) | (13) |
| Adrenal Medulla | (15) | (0) | (0) | (0) | (13) |
| Pituitary Gland | (14) | (0) | (0) | (0) | (12) |
| Thyroid Gland | (15) | (0) | (0) | (0) | (12) |
| GENERAL BODY SYSTEM | | | | | |
| None | | | | | |
| GENITAL SYSTEM | | | | | |
| Uterus | (1) | (0) | (0) | (0) | (0) |
| HEMATOPOIETIC SYSTEM | | | | | |
| Lymph Node, Mandibular | (15) | (0) | (0) | (0) | (12) |
| Spleen | (15) | (0) | (0) | (0) | (13) |
| Thymus | (15) | (0) | (0) | (0) | (12) |
| INTEGUMENTARY SYSTEM | | | | | |
| Mammary Gland | (15) | (0) | (0) | (0) | (12) |
| Skin | (15) | (0) | (0) | (0) | (13) |
| SOA, Squamous Cell Papilloma | 1 (7%) | | | | 3 (23%) |
| Squamous Cell Papilloma | 1 (7%) | | | | 1 (8%) |
| MUSCULOSKELETAL SYSTEM | | | | | |
| None | | | | | |
| NERVOUS SYSTEM | | | | | |
| None | | | | | |
| RESPIRATORY SYSTEM | | | | | |
| Lung | (15) | (0) | (0) | (0) | (13) |

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 91014-06
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/TG.AC HEMI

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)
CAS Number: 93-83-4

Date Report Requested: 10/23/2014
Time Report Requested: 09:28:42
First Dose M/F: NA / NA
Lab: ILS

| TG.AC HEMI Mouse FEMALE | 0 MG | 1.50 UG TPA | 0.4 MG | 0.8 MG | 1.2 MG |
|-------------------------|------|-------------|--------|--------|--------|
| <hr/> | | | | | |
| SPECIAL SENSES SYSTEM | | | | | |
| None | | | | | |
| <hr/> | | | | | |
| URINARY SYSTEM | | | | | |
| Kidney | (15) | (0) | (0) | (0) | (13) |

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 91014-06
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/TG.AC HEMI

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)

CAS Number: 93-83-4

Date Report Requested: 10/23/2014
Time Report Requested: 09:28:42
First Dose M/F: NA / NA
Lab: ILS

| TG.AC HEMI Mouse FEMALE | 0 MG | 1.50 UG TPA | 0.4 MG | 0.8 MG | 1.2 MG |
|--|------|-------------|--------|--------|--------|
| <hr/> | | | | | |
| Tumor Summary for FEMALE | | | | | |
| Total Animals with Primary Neoplasms (b) | 4 | | | | 5 |
| Total Primary Neoplasms | 8 | | | | 10 |
| Total Animals with Benign Neoplasms | 4 | | | | 5 |
| Total Benign Neoplasms | 6 | | | | 10 |
| Total Animals with Malignant Neoplasms | 2 | | | | |
| Total Malignant Neoplasms | 2 | | | | |
| Total Animals with Metastatic Neoplasms | | | | | |
| Total Metastatic Neoplasms | | | | | |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | | | |
| Total Animals with Neoplasms Uncertain - Benign or Malignant | | | | | |
| Total Uncertain Neoplasms | | | | | |

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically